<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784000</url>
  </required_header>
  <id_info>
    <org_study_id>AT-03A-004</org_study_id>
    <nct_id>NCT04784000</nct_id>
  </id_info>
  <brief_title>Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527</brief_title>
  <official_title>A Phase 1 Study Assessing the Effect of Carbamazepine, a P-Glycoprotein Inducer, on the Pharmacokinetics of AT-527 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atea Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effect of carbamazepine on the PK of AT-527 (RO7496998) in&#xD;
      healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Actual">April 10, 2021</completion_date>
  <primary_completion_date type="Actual">April 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of AT-527 (RO7496998)</measure>
    <time_frame>Day 1 vs Day 26</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of AT-527 (RO7496998)</measure>
    <time_frame>Day 1 vs Day 26</time_frame>
    <description>Area under the concentration-time curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>AT-527 550 mg + carbamezepine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-527 1100 mg + carbamezepine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period 1: AT-527 550 mg</intervention_name>
    <description>AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1</description>
    <arm_group_label>AT-527 1100 mg + carbamezepine</arm_group_label>
    <arm_group_label>AT-527 550 mg + carbamezepine</arm_group_label>
    <other_name>AT-527 is also known as RO7496998</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period 2: carbamazepine</intervention_name>
    <description>Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25</description>
    <arm_group_label>AT-527 1100 mg + carbamezepine</arm_group_label>
    <arm_group_label>AT-527 550 mg + carbamezepine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period 3: AT-527 550 mg + carbamazepine</intervention_name>
    <description>AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26</description>
    <arm_group_label>AT-527 550 mg + carbamezepine</arm_group_label>
    <other_name>AT-527 is also known as RO7496998</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period 3: AT-527 1100 mg + carbamazepine</intervention_name>
    <description>AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26</description>
    <arm_group_label>AT-527 1100 mg + carbamezepine</arm_group_label>
    <other_name>AT-527 is also known as RO7496998</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must agree to use two methods of birth control from Screening through 90 days after&#xD;
             administration of the last dose of study drug&#xD;
&#xD;
          -  Females must have a negative pregnancy test at Screening and prior to dosing&#xD;
&#xD;
          -  Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2&#xD;
&#xD;
          -  Willing to comply with the study requirements and to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
&#xD;
          -  Use of other investigational drugs within 28 days of dosing&#xD;
&#xD;
          -  Use of other prescription drugs with 28 days of dosing&#xD;
&#xD;
          -  Other clinically significant medical conditions or laboratory abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

